Valuation: Incyte Corporation

Market Cap 23.1B 20.25B 18.72B 17.22B 32.48B 2,228B 33.01B 224B 87.74B 1,090B 86.76B 84.87B 3,756B P/E 2026 *
76.5x
P/E 2027 * 15.9x
Enterprise Value 18.62B 16.32B 15.09B 13.88B 26.19B 1,796B 26.61B 180B 70.73B 879B 69.94B 68.41B 3,028B EV / Sales 2026 *
3.27x
EV / Sales 2027 * 2.81x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-1.38%
1 week+1.97%
Current month+1.14%
1 month+19.39%
3 months+23.48%
6 months+14.84%
Current year+21.19%
1 week 99.86
Extreme 99.86
103.15
1 month 85.18
Extreme 85.18
103.6
Current year 77.6
Extreme 77.6
103.6
1 year 57.22
Extreme 57.22
103.6
3 years 47.11
Extreme 47.11
103.6
5 years 47.11
Extreme 47.11
103.6
10 years 47.11
Extreme 47.11
144.13
Manager TitleAgeSince
Chief Executive Officer 58 2025-06-25
Director of Finance/CFO 57 2026-05-03
President 62 2023-06-04
Director TitleAgeSince
Chairman 59 2025-06-25
Director/Board Member 72 2015-01-19
Director/Board Member 64 2015-01-19
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%+1.97% - - 23.1B
-0.67%+1.37%+23.89%-7.04% 68.38B
+0.59%+2.97%+38.14%+191.88% 51.69B
-3.65%+34.50%+34.50%+34.50% 42.1B
-1.00%-1.28%-52.46%-54.56% 41.11B
-2.93%-4.34%+59.97%-27.21% 29.52B
-3.77%-11.22%+90.31%-52.32% 23.6B
-0.38%+2.33%+3.95%+180.95% 20.54B
-0.48%+1.50%+71.30%+121.11% 16.53B
-0.76%-2.79%+73.64%+134.15% 15.83B
Average -0.98%-1.63%+38.14%+57.94% 34.37B
Weighted average by Cap. -1.01%-1.06%+29.84%+46.72%

Financials

2026 *2027 *
Net sales 5.69B 4.99B 4.61B 4.24B 8B 548B 8.12B 55.1B 21.6B 268B 21.36B 20.89B 925B 6.14B 5.38B 4.97B 4.57B 8.63B 592B 8.77B 59.46B 23.31B 290B 23.05B 22.55B 998B
Net income 314M 275M 254M 234M 441M 30.28B 449M 3.04B 1.19B 14.82B 1.18B 1.15B 51.04B 1.47B 1.29B 1.19B 1.1B 2.07B 142B 2.1B 14.26B 5.59B 69.45B 5.53B 5.41B 239B
Net Debt -4.48B -3.93B -3.63B -3.34B -6.3B -432B -6.4B -43.4B -17.01B -211B -16.82B -16.46B -728B -5.86B -5.13B -4.75B -4.36B -8.24B -565B -8.37B -56.75B -22.25B -276B -22B -21.52B -952B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
26-07-21 101.70 -1.41% 0
26-07-20 €103.15 +2.94% 10
26-07-17 €100.20 +0.30% 0
26-07-16 €99.90 +0.04% 0
26-07-15 €99.86 +0.12% 45
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
115.65USD
Average target price
114.27USD
Spread / Average Target
-1.19%

Quarterly revenue - Rate of surprise